{"id":1648,"date":"2024-10-26T18:58:32","date_gmt":"2024-10-26T16:58:32","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/"},"modified":"2024-10-26T18:58:33","modified_gmt":"2024-10-26T16:58:33","slug":"utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/","title":{"rendered":"Utilisation \u00e0 long terme de l&rsquo;upadacitinib r\u00e9alisable chez les adolescents atteints de dermatite atopique"},"content":{"rendered":"<div>\n<div class=\"article-gallery lightGallery\">\n<div data-thumb=\"https:\/\/scx1.b-cdn.net\/csz\/news\/tmb\/2024\/long-term-upadacitinib.jpg\" data-src=\"https:\/\/scx2.b-cdn.net\/gfx\/news\/2024\/long-term-upadacitinib.jpg\" data-sub-html=\"\">\n<figure class=\"article-img\">\n<\/figure><\/div>\n<\/div>\n<p>Le traitement \u00e0 long terme des adolescents atteints de dermatite atopique (MA) mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re par l&rsquo;upadacitinib est s\u00fbr et efficace pendant 76 semaines, selon une \u00e9tude publi\u00e9e en ligne le 23 octobre dans <i>JAMA Dermatologie<\/i>.<\/p>\n<p>Amy S. Paller, MD, de la Feinberg School of Medicine de l&rsquo;Universit\u00e9 Northwestern \u00e0 Chicago, et ses coll\u00e8gues ont \u00e9valu\u00e9 l&rsquo;efficacit\u00e9 et les \u00e9v\u00e9nements ind\u00e9sirables de l&rsquo;upadacitinib chez des patients adolescents atteints de MA mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re pendant 76 semaines. L&rsquo;analyse comprenait les donn\u00e9es de 542 adolescents participant aux essais cliniques Measure Up 1, Measure Up 2 et AD Up.<\/p>\n<p>Les chercheurs ont constat\u00e9 qu&rsquo;\u00e0 la semaine 76, une r\u00e9duction \u2265 75 pour cent du score de l&rsquo;indice de zone et de gravit\u00e9 de l&rsquo;ecz\u00e9ma (EASI-75) a \u00e9t\u00e9 obtenue par 89,1, 84,4 et 87,8 pour cent des adolescents prenant 15 mg d&rsquo;upadacitinib dans les programmes Measure Up 1 et Measure Up 2. , et les essais AD Up, respectivement. Pour une dose de 30 mg, EASI-75 a \u00e9t\u00e9 atteint respectivement par 96,1, 93,6 et 82,7 pour cent des adolescents. Pour les deux doses d&rsquo;upadacitinib, les r\u00e9sultats ont indiqu\u00e9 un maintien ou une am\u00e9lioration de l&rsquo;EASI-75 sur 76 semaines. Les r\u00e9sultats \u00e0 long terme chez les participants \u00e0 l&rsquo;essai \u00e9taient coh\u00e9rents avec le profil d&rsquo;\u00e9v\u00e9nements ind\u00e9sirables connu de l&rsquo;upadacitinib (infection herp\u00e9tique\u00a0: 4,0, 1,9 et 1,1 \u00e9v\u00e9nements pour 100 ann\u00e9es-patients, respectivement\u00a0; \u00e9l\u00e9vation de la cr\u00e9atine kinase\u00a0: 11,6, 11,0 et 7,1 \u00e9v\u00e9nements pour 100 patients). -ann\u00e9es, respectivement), sans aucun nouveau signal observ\u00e9 avec l&rsquo;une ou l&rsquo;autre dose.<\/p>\n<p>\u00ab Bien que la diff\u00e9rence dans les proportions de patients atteignant au moins EASI-75 entre les deux groupes de traitement par l&rsquo;upadacitinib soit faible, la diff\u00e9rence entre les deux doses devient plus prononc\u00e9e au fil du temps dans les crit\u00e8res d&rsquo;efficacit\u00e9 les plus stricts, tels que EASI-90. \u00bb \u00e9crivent les auteurs.<\/p>\n<p>Plusieurs auteurs ont r\u00e9v\u00e9l\u00e9 des liens avec des soci\u00e9t\u00e9s pharmaceutiques, dont AbbVie, qui fabrique l&rsquo;upadacitinib et a financ\u00e9 l&rsquo;\u00e9tude.<\/p>\n<p>                                        <!-- print only --><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Le traitement \u00e0 long terme des adolescents atteints de dermatite atopique (MA) mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re<\/p>\n","protected":false},"author":1,"featured_media":1649,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[58,2028,282,56,2027,49,619,2025,2026,1637,717],"class_list":["post-1648","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-maladies","tag-adolescents","tag-atopique","tag-atteints","tag-chez","tag-dermatite","tag-les","tag-long","tag-lupadacitinib","tag-realisable","tag-terme","tag-utilisation","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Utilisation \u00e0 long terme de l&#039;upadacitinib r\u00e9alisable chez les adolescents atteints de dermatite atopique - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Utilisation \u00e0 long terme de l&#039;upadacitinib r\u00e9alisable chez les adolescents atteints de dermatite atopique - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"Le traitement \u00e0 long terme des adolescents atteints de dermatite atopique (MA) mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-26T16:58:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-26T16:58:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729961912_Utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"716\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"Utilisation \u00e0 long terme de l&rsquo;upadacitinib r\u00e9alisable chez les adolescents atteints de dermatite atopique\",\"datePublished\":\"2024-10-26T16:58:32+00:00\",\"dateModified\":\"2024-10-26T16:58:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/\"},\"wordCount\":354,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729961912_Utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents.jpg\",\"keywords\":[\"adolescents\",\"atopique\",\"atteints\",\"chez\",\"dermatite\",\"Les\",\"long\",\"lupadacitinib\",\"r\u00e9alisable\",\"terme\",\"Utilisation\"],\"articleSection\":[\"Les maladies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/\",\"name\":\"Utilisation \u00e0 long terme de l'upadacitinib r\u00e9alisable chez les adolescents atteints de dermatite atopique - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729961912_Utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents.jpg\",\"datePublished\":\"2024-10-26T16:58:32+00:00\",\"dateModified\":\"2024-10-26T16:58:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729961912_Utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729961912_Utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents.jpg\",\"width\":1280,\"height\":716,\"caption\":\"Utilisation \u00e0 long terme de l'upadacitinib r\u00e9alisable chez les adolescents atteints de dermatite atopique\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Utilisation \u00e0 long terme de l&rsquo;upadacitinib r\u00e9alisable chez les adolescents atteints de dermatite atopique\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Utilisation \u00e0 long terme de l'upadacitinib r\u00e9alisable chez les adolescents atteints de dermatite atopique - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/","og_locale":"fr_FR","og_type":"article","og_title":"Utilisation \u00e0 long terme de l'upadacitinib r\u00e9alisable chez les adolescents atteints de dermatite atopique - RVH-Synergie.org","og_description":"Le traitement \u00e0 long terme des adolescents atteints de dermatite atopique (MA) mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re","og_url":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/","og_site_name":"RVH-Synergie","article_published_time":"2024-10-26T16:58:32+00:00","article_modified_time":"2024-10-26T16:58:33+00:00","og_image":[{"width":1280,"height":716,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729961912_Utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"Utilisation \u00e0 long terme de l&rsquo;upadacitinib r\u00e9alisable chez les adolescents atteints de dermatite atopique","datePublished":"2024-10-26T16:58:32+00:00","dateModified":"2024-10-26T16:58:33+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/"},"wordCount":354,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729961912_Utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents.jpg","keywords":["adolescents","atopique","atteints","chez","dermatite","Les","long","lupadacitinib","r\u00e9alisable","terme","Utilisation"],"articleSection":["Les maladies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/","url":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/","name":"Utilisation \u00e0 long terme de l'upadacitinib r\u00e9alisable chez les adolescents atteints de dermatite atopique - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729961912_Utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents.jpg","datePublished":"2024-10-26T16:58:32+00:00","dateModified":"2024-10-26T16:58:33+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729961912_Utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729961912_Utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents.jpg","width":1280,"height":716,"caption":"Utilisation \u00e0 long terme de l'upadacitinib r\u00e9alisable chez les adolescents atteints de dermatite atopique"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/utilisation-a-long-terme-de-lupadacitinib-realisable-chez-les-adolescents-atteints-de-dermatite-atopique\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"Utilisation \u00e0 long terme de l&rsquo;upadacitinib r\u00e9alisable chez les adolescents atteints de dermatite atopique"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/1648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=1648"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/1648\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/1649"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=1648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=1648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=1648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}